Home › NDC Lookup › RxCUI directory › RxCUI 2102779

Revefenacin 0.0583 MG/ML Inhalation Solution — RxCUI 2102779

RxNorm drug concept · Semantic clinical drug
RxCUI 2102779 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2102779
Official nameRevefenacin 0.0583 MG/ML Inhalation Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asrevefenacin 175 MCG per 3 ML Inhalation Solution; revefenacin 175 MCG in 3 ML Inhalation Solution
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)20,174 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Revefenacin Oral Inhalation: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yupelri is a maintenance medicine — you use it every single day to keep your airways open and make day-to-day breathing easier with COPD. It is not a rescue inhaler. If you're havi...
  • What exactly is Yupelri for, and will it help me during a flare-up?
  • You open the single-dose vial right before your treatment — not ahead of time — and pour the liquid into a standard jet nebulizer connected to an air compressor. You breathe the mi...
  • The most common side effects are pretty mild — cough, cold-like symptoms, headache, and back pain. Some people notice dry mouth over time. What you really want to watch for are war...
📖 Read our full Revefenacin Oral Inhalation guide →

🕸️ Concept Web — How Revefenacin 0.0583 MG/ML Inhalation Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Revefenacin 0.0583 MG/ML Inhalation Solution RxCUI 2102779

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Revefenacin 2102775
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Yupelri 2102780
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Revefenacin Inhalation Solution 2108378
    • Revefenacin Inhalant Product 2102777
    • Revefenacin Inhalation Solution [Yupelri] 2108380
    • Yupelri Inhalant Product 2102783
    • Inhalation Solution 346161
    • Inhalant Product 1151123
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Revefenacin 0.0583 MG/ML SCDC · 2102776
  • Revefenacin Inhalation Solution SCDF · 2108378
  • Revefenacin Inhalant Product SCDG · 2102777

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2102779 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49502-0806-87 7 POUCH in 1 CARTON (49502-806-87) / 1 VIAL, SINGLE-DOSE in... YUPELRI Viatris Specialty LLC 2019-01-01
49502-0806-93 30 POUCH in 1 CARTON (49502-806-93) / 1 VIAL, SINGLE-DOSE i... YUPELRI Viatris Specialty LLC 2018-12-03
Observed labelers: Viatris Specialty LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$17.4825
Range $17.4825–$17.4825 · middle 50% $17.4825–$17.4825 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J7677 Revefenacin inh non-com 1mcg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.